Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t an Option - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn't an Option 12/19/2024 The findings from a recent NCI-supported clinical trial are helpful because previous studies for people with locally advanced head and neck cancer have yielded conflicting data for and against several alternatives to cisplatin combined with radiation. You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892